TNFRSF17 and Miyoshi myopathy: The breakthrough of anti-BCMA immunotherapy in MM was reported in preclinical studies on the first chimeric antigen receptor (CAR) T cells in 2013 [29] and the anti-BCMA J6M0 with engineered Fc conjugated with MMAF via uncleavable linker in 2014 [28].